Alkem Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 25, 2025
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories has notified the exchanges about its 51st Annual General Meeting scheduled for Monday, August 25, 2025, at 11:00 a.m. via video conferencing, along with the release of its Annual Report for FY2024-25. For FY2025, consolidated revenue stood at ₹1,29,645 million, up 2.3% year-on-year, while profit after tax surged 20.6% to ₹21,655 million and EBITDA grew 11.9% to ₹25,122 million, with EBITDA margin expanding from 17.7% to 19.4%. Domestic India sales rose 6.5% to ₹89,837 million, contributing about 70% of total revenue, while the US business saw de-growth due to pricing pressure; rest-of-world markets grew 8.7% led by Australia and key European countries. The company strengthened its balance sheet with net cash of ₹46.2 billion, paid a dividend of ₹45 per share, and made strategic moves including acquisitions in derma cosmetology (Adroit) and orthopaedics (Bombay Ortho), entry into MedTech via Alkem MedTech, and inclusion in the MSCI India Index. R&D spend was ₹5,620 million with 156 ANDAs and 2 NDAs approved by USFDA cumulatively till FY2025.
This is a routine AGM notice, but the attached annual report signals strong profitability growth (PAT up 20.6%) and margin expansion. Shareholders should review the annual report for dividend details, governance updates, and vote on resolutions at the August 25 meeting; the company's expansion into MedTech, biologics, and global markets could support long-term growth, though US pricing pressure remains a watchpoint.